Lantheus (LNTH) to Announce Quarterly Earnings on Wednesday

Lantheus (NASDAQ:LNTH) will likely be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $1.33 per share and revenue of $362.4480 million for the quarter. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same period in the previous year, the company earned $1.53 earnings per share. Lantheus’s quarterly revenue was up 1.2% compared to the same quarter last year. On average, analysts expect Lantheus to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Lantheus Stock Performance

NASDAQ LNTH opened at $102.64 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. Lantheus has a 1 year low of $47.25 and a 1 year high of $111.86. The company has a market capitalization of $6.68 billion, a PE ratio of 24.73 and a beta of -0.06. The company has a fifty day moving average of $103.85 and a two-hundred day moving average of $86.19.

Analysts Set New Price Targets

Several research firms have recently weighed in on LNTH. Mizuho boosted their target price on Lantheus from $115.00 to $120.00 and gave the company a “market outperform” rating in a report on Wednesday, July 15th. Citizens Jmp restated a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a research note on Monday, June 29th. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Finally, B. Riley Financial raised their target price on shares of Lantheus from $97.00 to $129.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $110.43.

Institutional Investors Weigh In On Lantheus

Several large investors have recently modified their holdings of LNTH. Osterweis Capital Management Inc. acquired a new stake in shares of Lantheus in the 2nd quarter worth $36,000. Smartleaf Asset Management LLC raised its holdings in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Parallel Advisors LLC raised its holdings in Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Lantheus in the fourth quarter valued at about $39,000. Finally, EFG International AG acquired a new stake in Lantheus in the fourth quarter valued at about $60,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.